menu
    • menu
    [{"orgOrder":0,"company":"Aeterna Zentaris","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Macimorelin","moa":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Aeterna Zentaris","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Aeterna Zentaris \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Aeterna Zentaris \/ Not Applicable"},{"orgOrder":0,"company":"Aeterna Zentaris","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"","productType":"Small molecule","year":"2020","type":"Public Offering","leadProduct":"Macimorelin","moa":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Aeterna Zentaris","amount2":0.01,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","amount2New":0.01,"dosageForm":"Solution","sponsorNew":"Aeterna Zentaris \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"12","companyTruncated":"Aeterna Zentaris \/ H.C. Wainwright & Co."},{"orgOrder":0,"company":"Aeterna Zentaris","sponsor":"Novo Nordisk","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"","productType":"Small molecule","year":"2022","type":"Termination","leadProduct":"Macimorelin","moa":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Aeterna Zentaris","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Aeterna Zentaris \/ Novo Nordisk","highestDevelopmentStatusID":"12","companyTruncated":"Aeterna Zentaris \/ Novo Nordisk"},{"orgOrder":0,"company":"Ceapro","sponsor":"Aeterna Zentaris","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Merger","leadProduct":"Macimorelin","moa":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Ceapro","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Ceapro \/ Aeterna Zentaris","highestDevelopmentStatusID":"4","companyTruncated":"Ceapro \/ Aeterna Zentaris"},{"orgOrder":0,"company":"Ceapro","sponsor":"Aeterna Zentaris","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2024","type":"Merger","leadProduct":"Macimorelin","moa":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Ceapro","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Ceapro \/ Aeterna Zentaris","highestDevelopmentStatusID":"4","companyTruncated":"Ceapro \/ Aeterna Zentaris"}]

    Find Clinical Drug Pipeline Developments & Deals for Macimorelin

    Menu

    Macimorelin

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Ceapro

                            Canada arrow
                            CPhI India 2024
                            Not Confirmed

                            Ceapro

                            Canada arrow
                            CPhI India 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Macimorelin

                            Therapeutic Area : Neurology

                            Study Phase : Preclinical

                            Sponsor : Aeterna Zentaris

                            Deal Size : Undisclosed

                            Deal Type : Merger

                            DEALS_DEV arrow-down

                            Aeterna Zentaris and Ceapro Complete Merger Transaction

                            Details : The combined company will focus on the development of AEZS-130 (macimorelin), a ghrelin receptor agonist and a small molecule that stimulates the secretion of growth hormone from the pituitary gland.

                            Brand Name : AEZS-130

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            June 03, 2024

                            Lead Product(s) : Macimorelin

                            Therapeutic Area : Neurology

                            Highest Development Status : Preclinical

                            Sponsor : Aeterna Zentaris

                            Deal Size : Undisclosed

                            Deal Type : Merger

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Ceapro

                            Canada arrow
                            CPhI India 2024
                            Not Confirmed

                            Ceapro

                            Canada arrow
                            CPhI India 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Macimorelin

                            Therapeutic Area : Neurology

                            Study Phase : Preclinical

                            Sponsor : Aeterna Zentaris

                            Deal Size : Undisclosed

                            Deal Type : Merger

                            DEALS_DEV arrow-down

                            Aeterna Zentaris and Ceapro Announce Merger of Equals to Create a Diversified Biopharmaceutical Company

                            Details : The combined company will focus on the development of AEZS-130 (macimorelin), a ghrelin receptor agonist and a small molecule that stimulates the secretion of growth hormone from the pituitary gland.

                            Brand Name : AEZS-130

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            December 14, 2023

                            Lead Product(s) : Macimorelin

                            Therapeutic Area : Neurology

                            Highest Development Status : Preclinical

                            Sponsor : Aeterna Zentaris

                            Deal Size : Undisclosed

                            Deal Type : Merger

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Aeterna Zentaris

                            U.S.A arrow
                            CPhI India 2024
                            Not Confirmed

                            Aeterna Zentaris

                            U.S.A arrow
                            CPhI India 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Macimorelin

                            Therapeutic Area : Endocrinology

                            Study Phase : Approved

                            Sponsor : Novo Nordisk

                            Deal Size : Undisclosed

                            Deal Type : Termination

                            DEALS_DEV arrow-down

                            Aeterna Zentaris Set to Regain Full Rights to Macrilen™ (Macimorelin) in U.S. and Canada from Novo Nordisk

                            Details : Under the Commercial License, Novo Nordisk was granted an exclusive license for the development, manufacturing, registration and commercialization of Macrilen™ (macimorelin) in the U.S. and Canada.

                            Brand Name : Macrilen

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            August 29, 2022

                            Lead Product(s) : Macimorelin

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Approved

                            Sponsor : Novo Nordisk

                            Deal Size : Undisclosed

                            Deal Type : Termination

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Aeterna Zentaris

                            U.S.A arrow
                            CPhI India 2024
                            Not Confirmed

                            Aeterna Zentaris

                            U.S.A arrow
                            CPhI India 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Macimorelin

                            Therapeutic Area : Endocrinology

                            Study Phase : Approved

                            Sponsor : H.C. Wainwright & Co.

                            Deal Size : $12.0 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            Aeterna Zentaris Announces Pricing of $12 Million Public Offering

                            Details : The Company intends to use the net proceeds of this offering for general corporate purposes, which includes funding of a pediatric clinical trial in the E.U. and U.S. for Macrilen, the investigation of further therapeutic uses of macimorelin.

                            Brand Name : Macrilen

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            July 01, 2020

                            Lead Product(s) : Macimorelin

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Approved

                            Sponsor : H.C. Wainwright & Co.

                            Deal Size : $12.0 million

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Aeterna Zentaris

                            U.S.A arrow
                            CPhI India 2024
                            Not Confirmed

                            Aeterna Zentaris

                            U.S.A arrow
                            CPhI India 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Macimorelin

                            Therapeutic Area : Endocrinology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Aeterna Zentaris Announces Positive Results In Dose-Finding Pediatric Study Of Macimorelin

                            Details : Positive results provide clinical framework to advance the Company’s Pediatric Investigation Plan for macimorelin as a growth hormone deficiency diagnostic.

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            April 06, 2020

                            Lead Product(s) : Macimorelin

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth